The degree of blood pressure (BP) response to antihypertensive treatment can differ according to the baseline characteristics of patients under treatment for hypertension. Genotype, 1 ethnicity, 2 heart rate, 3 plasma renin activity, 4 and arterial stiffness 5 have been shown to be predictors of BP reduction response to antihypertensive drugs. Adequate BP reduction, independent of the class of antihypertensive agent, is the cornerstone of successful reduction of cardiovascular risk. 6, 7 Therefore, the identification of poor responders to medication might be clinically beneficial as a strategy for individualization of antihypertensive treatment.
Several biomarkers have been identified for estimation of total cardiovascular risk in hypertensive patients, and recent international guidelines recommend stratifying the cardiovascular risk of patients at baseline according to these biomarkers and the type of subclinical organ damage. 8, 9 High-sensitivity C-reactive protein (hsCRP), a marker of inflammation, has been associated with the pathogenesis of atherosclerosis and future incidence of cardiovascular events. [10] [11] [12] It is a recommended biomarker for assessment of total cardiovascular risk in hypertensive patients. 9 There is also accumulating evidence that increased hsCRP is associated with new-onset and progression of hypertension, suggesting that hsCRP may play a pathophysiological role in BP elevation itself. 13 These findings raise the possibility that the baseline hsCRP level may predict both future cardiovascular events and the degree of BP response to antihypertensive treatment.
Based on this hypothesis, we investigated the relationship between baseline hsCRP level and response of clinic BP and ambulatory BP to antihypertensive treatment as the subanalysis of the ALPHABET study, in which the antihypertensive effects of losartan/hydrochlorothiazide (HCTZ) and highdose amlodipine were examined. 14 
Methods study design
This study was a multicenter, open-label, randomized trial designed to compare the effects of losartan/HCTZ combination therapy and high-dose amlodipine monotherapy on clinic and out-of clinic BP. The protocol of the ALPHABET study has been described in detail elsewhere. 14 Briefly, each untreated hypertensive patient was randomly allocated to one of the two groups that received either 50 mg losartan or 5 mg amlodipine for 4 weeks. The 50 mg losartan was changed to a fixed-dose combination of 50 mg losartan/12.5 mg HCTZ after this monotherapy period, and the dose of amlodipine was titrated to 10 mg for a further 4 weeks ( Figure 1 ). All patients were instructed to take their antihypertensive medications just after breakfast.
The ethics committee of the internal review board of the Jichi Medical University School of Medicine, Tochigi, Japan, approved the protocol. The study was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000002438).
study patients
A total of 91 hypertensive outpatients were enrolled between April 2008 and March 2009 by 6 physicians at 4 institutions (1 primary practice, 1 hospital-based outpatient clinic, and 2 specialized university hospitals). Of these patients, 88 (n = 46 men, n = 42 women; mean age = 63.4 ± 13.2 years old) with complete data for clinic BP, ambulatory BP monitoring (ABPM), and blood tests at baseline and at the end of the study were subjected to analysis (Figure 2 ). Hypertension was defined as an average seated clinic systolic BP (SBP) > 140 mm Hg or diastolic BP (DBP) > 90 mm Hg on >2 different occasions during the run-in period (2 weeks). None of the patients had received any antihypertensive medication for at least 1 month before the start of the study. The patients were excluded if they had secondary hypertension, uncontrolled hypertension (DBP > 120 mm Hg), uncontrolled diabetes mellitus (HbA1c > 8.0%), renal insufficiency (serum creatinine > 2 mg/dl), hyperuricemia (>8.0 mg/dl), moderate to severe symptoms of heart failure (>New York Heart Association class III), a history of myocardial infarction and stroke within the last 3 months, severe hepatic disease, chronic inflammatory disease, bilateral renal artery stenosis, or allergy/hypersensitivity to drugs used in this study. Smokers were defined as current smokers and patients with a history of smoking within 3 months before entry into this study. Dyslipidemia was defined as a low-density lipoprotein cholesterol concentration > 140 mg/ dl, or high-density lipoprotein cholesterol concentration < 40 mg/dl, or triglyceride concentration > 150 mg/dl, or current use of antilipidemic medication. Written informed consent was obtained from all subjects.
Blood pressure measurements
The clinic BP was recorded as the average of triplicate measurements taken at intervals of 15 seconds using a validated oscillometric device (HEM-5041; Omron Healthcare, Kyoto, Japan) at each visit after an initial seated rest for 5 minutes. BP measurements at intervals of 15 seconds have been shown to be as accurate as conventional BP measurements made at 1-minute intervals. 15 Ambulatory BP measurements were carried out twice on 2 separate weekdays with 1 of 2 automatic ABPM devices (TM2425 or TM2431; A&D, Tokyo, Japan), which recorded the BP and pulse rate by the oscillometric method every 30 minutes for 24 hours. The first ABPM was performed at the end of the run-in period, and the second ABPM was performed at the end of the 8-week treatment period. The 24-hour BP was defined as the average of all BP readings recorded, including both daytime and nighttime readings. The subjects were all ambulant during the day, and no subjects reported staying in bed after awakening. Nighttime BP was defined as the average of the BP from the time when patients went to bed until the time they got out of bed; daytime BP was defined as the average of BP recorded during the rest of the day.
Blood examination
Blood and urine samples were collected in the morning in a fasting state at enrollment and at the end of the study. The blood samples were centrifuged at 3,000 × g for 15 minutes at room temperature. Plasma/serum and urine samples were stored at 4 °C in refrigerated containers and sent to a commercial laboratory (SRL, Tokyo, Japan) within 24 hours. All assays were performed within 24 hours of sample collection at this single laboratory center. The serum hsCRP was measured with latex-enhanced nephelometry (N-latex CRP-2; Siemens Healthcare, Tokyo, Japan). Serum creatinine was measured by enzymatic methods and then quantified by a photometric method.
statistical analysis
All statistical analyses were carried out using the SPSS software package, version 11.0 (SPSS, Chicago, IL). Data are expressed as the means (± SD) or percentages. The distribution of all parameters was checked by KolmogorovSmirnov test before analysis. Clinical parameters between 2 groups were compared using the unpaired Student t test for normally distributed variables. Categorical parameters were compared with the χ 2 test. The hsCRP were log-transformed before the statistical analysis because the distribution was highly skewed, and these data were expressed as the geometric mean. A 2-tailed paired t test was used to compare the mean values between baseline and after treatment for each treatment group. Univariable linear regression analysis between the baseline log-transformed hsCRP and percentage changes in BPs were assessed using Pearson correlations. Multivariable linear regression analysis was used to explore the associations of the percentage change in 24-hour SBP or daytime SBP, adjusting for covariables including age, male sex, body mass index, dyslipidemia, and smoking. The associations/differences with a P value < 0.05 (2-tailed) were considered to be statistically significant. In this post hoc analysis of the ALPHABET study, a sample size of 88 participants (44 per group) was sufficient to achieve at least 80% power to detect a difference of 6 mm Hg in BP between the below-and above-median hsCRP groups using Student t test, assuming a 2-sided significance level of 5% and a standard deviation of 10 mm Hg.
results

Baseline data
The flow of patients through each stage of the study is shown in Figure 1 and is also described elsewhere. 14 The baseline characteristics, laboratory data, and hemodynamic parameters were similar between the 2 treatment groups (Table 1) . Three patients (1 in the losartan/HCTZ group, 2 in the amlodipine group) withdrew and did not undergo blood and urine examinations and ABPM at the end of the study. Therefore, a total of 88 patients were analyzed in the present study. Eight patients in the losartan/HCTZ group and 9 patients in the amlodipine group showed a marked BP reduction during the first 4-week period, thus titration of these patients was not performed based on a physician's decision (Figure 2) . Therefore, the data in Figure 3 include those for 8 patients who received only 50 mg losartan, and the data in Figure 4 include those for 9 patients who received only 5 mg amlodipine at the end of the study. The median hsCRP level in the total population was 0.47 mg/L, and this was defined as a cutoff value for identifying above-median and below-median hsCRP. "Low-grade inflammation" was defined as a condition in which a patient has an hsCRP level above the median. Table 2 shows the baseline characteristics between the below-median hsCRP and the above-median hsCRP. Body mass index level (P = 0.02) and prevalence of dyslipidemia (P = 0.03) were significantly higher in the above-median hsCRP group than the below-median hsCRP group.
changes in blood pressure in below-median hscrP group and above-median hscrP group
The background of patients in the 2 treatment groups were similar in the below-and above-median hsCRP groups (Table 2 ). There was no significant difference in the baseline values of clinic BP and ambulatory 24-hour BP, daytime BP, and nighttime BP between the below-median hsCRP group and the above-median hsCRP group (Table 3) . However, the 24-hour SBP (P = 0.03) and daytime SBP (P = 0.01) were significantly higher in the above-median hsCRP group than in the below-median hsCRP group after 8 weeks of antihypertensive treatment. In contrast, the nighttime SBP and DBP did not differ significantly between the groups after 8 weeks of treatment. In the total population, the percentage changes in 24-hour SBP (−13.3 vs. −9.1%; P = 0.02) and daytime SBP (−13.3 vs. −8.4%; P = 0.004) and daytime DBP (−11.9 vs. −7.6%; P = 0.03) were significantly smaller in the above-median hsCRP group than in the below-median hsCRP group, whereas other changes in BPs were equivalent Univariable linear regression analyses were performed to assess the association between baseline hsCRP and percentage changes of BPs. These analyses showed that logtransformed baseline hsCRP was significantly correlated with percentage changes in 24-hour SBP (r = 0.28; P = 0.02) and daytime SBP (r = 0.34; P = 0.003), but not with changes in other BP values. The results of multiple linear regression analysis between the baseline hsCRP value and percentage changes in 24-hour SBP or daytime SBP are shown in Table 4 . The log-transformed baseline hsCRP showed a significant correlation with the percentage change in daytime SBP (β = 0.29; P = 0.02), even after adjusting for covariables including age, male sex, body mass index, smoking, and dyslipidemia.
discussion
There was no difference in clinic BP reduction to antihypertensive treatment between patients with below-median and above-median baseline hsCRP in this study. However, the antihypertensive response in the 24-hour BP and daytime BP were smaller in patients with above-median baseline hsCRP than in those with below-median baseline hsCRP. This suggests that baseline low-grade inflammation may be associated with difficult-to-treat hypertension, particularly in ambulatory BP. The difference in the predictive value of hsCRP for clinic BP response and ambulatory BP response is clinically interesting. The reason for this finding is unclear, but it may be associated with the reproducibility of BP measurements. Ambulatory BP, which is evaluated with multiple measurements, shows better reproducibility than clinic BP, 16, 17 and the reproducibility of ABPM is fairly good both in untreated and treated hypertensive patients. 18 This suggests that ABPM is a more feasible method for accurate evaluation of antihypertensive effects than clinic BP measurement, especially when the sample size is small. This may explain why baseline hsCRP showed a significant association with only the ambulatory BP response.
Interestingly, this study revealed that an above-median level of hsCRP was associated with poor daytime BP, but not nighttime BP, reduction in response to treatment. Smoking affects the daytime BP elevation but not the nighttime BP 19, 20 and also enhances the oxidative stress and vascular inflammation. 21 However, the significant association between baseline hsCRP and daytime BP reduction remained even after adjustment for covariables, including smoking. Therefore, it is unlikely that smoking accounts for this association. The above-median hsCRP group had a higher body mass index and prevalence of dyslipidemia. Obesity and hyperlipidemia are determinants of workplace hypertension in the Japanese population 22 and may be associated with BP elevation in the presence of increased activity and stress. Therefore, the results of this study may be partly due to the presence of obesity-related disease, which is associated with increased CRP. 12 Daytime BP is usually measured under the influence of physical activity and psychological stress. Kario et al. reported that the increase of awake physical activity and reactivity of BP to changes in activity are determinants of increased awake BP variability. 23 Increased inflammation has also been associated with an enhanced BP elevation response to psychological stress 24 and exercise. 25 The mechanisms of these relationships have not been investigated in detail, but it is possible that inflammation may adversely affect the sympathetic nervous system, carotid baroreflex function, and Multivariate linear regression analyses were adjusted by age and male sex. Change in BP (%) = (BP after 8 weeks of treatment) − (BP at baseline) / (BP at baseline) × 100. Dyslipidemia: yes = 1, no = 0. Smoker: yes = 1, no = 0.
Abbreviations: BMI, body mass index; hsCRP, high-sensitivity C-reactive protein.
vascular endothelial function, contributing to an increase of BP reactivity. 26, 27 Therefore, BP reactivity could be enhanced by an increased inflammatory status, consequently leading to the daytime BP elevation that would be difficult to control with antihypertensive medication. In this study, subjects treated with losartan/HCTZ with an above-median hsCRP showed a significantly smaller reduction in the 24-hour SBP, daytime SBP, and daytime DBP, in comparison with those with a below-median hsCRP. These findings were the same as those documented in the total population, suggesting that angiotensin type 1 receptor blocker and diuretic combination therapy were less effective on ambulatory BP reduction in patients showing an above-median level of hsCRP. In the latest subanalysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, 28 angiotensin-converting enzyme inhibitor and HCTZ combination therapy was less efficacious in preventing cardiovascular events than an angiotensin-converting enzyme inhibitor and calcium-channel blocker combination in nonobese patients. It was suggested that increased sympathetic nerve activity caused by diuretics might explain this result. The poor ambulatory BP response to losartan/HCTZ therapy might be based on the same mechanism, especially in patients with a higher inflammatory status. In contrast, patients in the amlodipine group with above-median and below-median hsCRP had similar reductions of clinic BP and all ambulatory BP parameters, suggesting that the antihypertensive effect of high-dose amlodipine was independent of the baseline inflammatory status in patients. This favorable result for amlodipine may be due to its strong and long-acting vasodilating effect. Rothwell et al. reported that in comparison with other drug classes, including angiotensin type 1 receptor blockers and diuretics, calcium-channel blockers reduced interindividual variation in BP. 29 Interindividual variability (i.e., group variance of BP during treatment) is likely to express variability in the BP response to hypertensive treatment. This study is the first report revealing that BP reduction with a calciumchannel blocker is not dependent on the hsCRP level, which partly supports the above observation that this class of drugs is associated with a small interindividual variation in BP-lowering effects. Therefore, it is possible that longacting calcium-channel blocker-based treatment, rather than angiotensin type 1 receptor blocker/diuretic therapy, is an optimal choice for 24-hour BP control, particularly in the daytime period in patients with an above-median level of hsCRP.
This study has several limitations. First, the period of this study was relatively short (8 weeks), and it is possible that long-term treatment would give different results. Second, hsCRP was the only marker of inflammation that was investigated. Third, we did not evaluate any measurements of physical activity during ABPM. Fourth, clinic, 24-hour, daytime, and nighttime BP are measured under various conditions and have differential clinical values. Therefore, we separately analyzed the changes of these BP parameters with Student t test as a priori comparison. Fifth, this study was a post hoc analysis, and the sample size was small, especially for analysis of 2 different treatment groups. In Table 4 , we demonstrated multiple regression analysis in the total population. Therefore, a significant linear relationship between hsCRP and daytime SBP change could not be generalized for both treatment groups. A large-scale trial is needed to determine if hsCRP is a predictor of BP response to all antihypertensive drugs or just to combination therapy with angiotensin type 1 receptor blockers and diuretics.
In conclusion, hsCRP was found to be a predictor of an ambulatory BP response to antihypertensive treatment but not of a clinic BP response. The ambulatory BP-lowering effect differed between losartan/HCTZ and high-dose amlodipine therapy in subjects with an above-median baseline level of hsCRP. This suggests that an initial measurement of hsCRP may be useful for establishing a strategy for successful 24-hour BP control in clinical management of hypertension.
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